Compare BBNX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBNX | STTK |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 538.3M |
| IPO Year | N/A | 2020 |
| Metric | BBNX | STTK |
|---|---|---|
| Price | $14.61 | $4.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $23.80 | $10.00 |
| AVG Volume (30 Days) | 780.1K | ★ 860.8K |
| Earning Date | 04-21-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $34.90 | N/A |
| Revenue Next Year | $34.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.80 | $0.71 |
| 52 Week High | $32.71 | $8.33 |
| Indicator | BBNX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 71.48 | 28.36 |
| Support Level | $9.34 | $3.67 |
| Resistance Level | $15.53 | $4.23 |
| Average True Range (ATR) | 0.96 | 0.51 |
| MACD | 0.27 | -0.15 |
| Stochastic Oscillator | 91.73 | 27.29 |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.